Clearance of Inflammatory Cytokines in Patients With Septic Acute Kidney Injury During Renal Replacement Therapy Using the EMIC®2 Filter
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Removal of inflammatory mediators
研究概览
简要总结
This study will be conducted in patients with sepsis and acute kidney injury needing renal replacement therapy.
The aim is to investigate whether continuous renal replacement therapy with the EMIC®2 filter leads to removal of pro-inflammatory middle molecular weight cytokines from the blood.
详细描述
In patients with acute kidney injury (AKI) and sepsis requiring renal replacement therapy, the investigators aim to determine whether continuous veno-venous haemodialysis with an EMiC®2 filter leads to clearance of the following mediators Interleukin (IL) -1 alpha, IL-1 beta, IL-2, IL- 4, IL-6, IL-8, IL-10, Tissue necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), Interferon gamma, Monocyte chemotactic protein-1 and epidermal growth factor.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adult patients (≥18 years) in the Critical Care Unit with AKI and sepsis
- •clinical decision that citrate based continuous veno-venous haemodialysis (CVVHD) is necessary
排除标准
- •lack of consent
- •pre-existing dialysis dependent renal failure
- •life expectancy <24 hours
- •patients with haemoglobin <7g/dL (unless transfused for clinical reasons)
- •need for extracorporeal membrane oxygenation (ECMO)
结局指标
主要结局
Removal of inflammatory mediators
时间窗: 48 hours
Clearance of the following mediators Interleukin (IL) -1 alpha, IL-1 beta, IL-2, IL- 4, IL-6, IL-8, IL-10, Tissue necrosis factor alpha (TNF-α), vascular endothelial growth factor (VEGF), Interferon gamma, Monocyte chemotactic protein-1 and epidermal growth factor
次要结局
- Adsorption of inflammatory mediators(48 hours)